恶性淋巴瘤患者细胞活化因子的表达及其临床意义  

Expressions of cell activating factors in patients with malignant lymphoma and their clinical significances

作　　者：康丽莉[1] 景传红[1] 朱颖[1] 陈益飞[1] 

机构地区：[1]江苏省扬州市江都人民医院血液科,225200

出　　处：《白血病．淋巴瘤》2018年第1期49-52,共4页Journal of Leukemia & Lymphoma

摘　　要：目的 探讨内皮细胞、中性粒细胞及血小板异常活化对恶性淋巴瘤进展及继发易栓症的影响.方法 采用酶联免疫吸附试验（ELISA）测定2009年10月至2016年11月扬州市江都人民医院40例恶性淋巴瘤患者及30名健康对照者血清中细胞活化因子可溶性血栓调节蛋白（sTM）水平,流式细胞术（FCM）测定抗凝全血中性粒细胞表面CD11b和血小板表面CD62p水平.检测结果组间比较采用方差分析及LSD-t检验.结果 恶性淋巴瘤患者治疗前血清中sTM表达水平为（49.7±9.3）ng/ml,高于治疗后的（6.3±1.8）ng/ml及对照组的（5.6±1.5）ng/ml（F=736.633,P=0.000）,治疗前与治疗后及对照组两两比较,差异均有统计学意义（t=33.789,P=0.000;t=31.782,P=0.000）.恶性淋巴瘤患者治疗前中性粒细胞表面CD11b平均荧光强度（MFI）为184±43,高于治疗后的118±12及对照组的112±15（F=101.845,P=0.000）,治疗前与治疗后及对照组两两比较,差异均有统计学意义（t=12.228,P=0.000;t=12.184,P=0.000）.恶性淋巴瘤患者治疗前血小板表面CD62p表达水平为（6.4±2.4）％,高于治疗后的（1.2±0.7）％及对照组的（1.3±0.5）％（F=141.481,P=0.000）,治疗前与治疗后及对照组两两比较,差异均有统计学意义（t=15.010,P=0.000;t=13.679,P=0.000）.结论 细胞活化因子表达水平与恶性淋巴瘤进展有关,内皮细胞、中性粒细胞及血小板异常活化促进了恶性淋巴瘤的发展,同时它们的相互作用可能会导致易栓状态.Objective To investigate the effects of endothelial cell, neutrophil and platelet activation on the development and thrombophilia of malignant lymphoma. Methods The levels of cell activating factors soluble thrombomodulin （sTM） in 40 patients with malignant lymphoma and 30 healthy controls in Jiangdu People ＇＇s Hospital of Yangzhou from October 2009 to November 2016 were tested by enzyme linked immunoabsorbent assay （ELISA）. The flow cytometry （FCM） method was used to measure the level of CD11b on the surface of anti-freezing whole blood neutrophil and CD62p on the surface of platelet. The results were analyzed by ANOVA and LSD-t test. Results The level of sTM in patients with malignant lymphoma before treatment was significantly higher than that after treatment and in the control group [（49.7±9.3） ng/ml vs. （6.3± 1.8） ng/ml, （5.6±1.5） ng/ml respectively;F=736.633, P=0.000]. There were significant differences between the levels before and after treatment and before treatment and in the control group （t= 33.789, P= 0.000;t=31.782, P=0.000）. The average fluorescence intensity （MFI） of neutrophil surface CD11b in patients with malignant lymphoma before treatment was significantly higher than that after treatment and in the control group （184 ± 43 vs. 118 ± 12, 112 ± 15 respectively; F=101.845, P=0.000）. There were significant differences between the levels before and after treatment and before treatment and in the control group （t=12.228, P= 0.000; t= 12.184, P= 0.000）. The level of platelet surface CD62p in patients with malignant lymphoma before treatment was significantly higher than that after treatment and in the control group [（6.4 ± 2.4） % vs. （1.2 ± 0.7） %, （1.3 ± 0.5） % respectively; F= 141.481, P= 0.000]. There were significant differences between the levels before and after treatment and before treatment and in the control group （t=15.010, P= 0.000; t= 13.679, P= 0.000）. Conclusions The levels of cell activating factors might be correlat

关 键 词：淋巴瘤 血栓调节蛋白 抗原 CD11b 抗原 CD62p 血栓形成倾向 

分 类 号：R733.1[医药卫生—肿瘤]